文献速递免疫规划妇幼与学校卫生

加拿大安大略省5至11岁儿童COVID-19疫苗对奥密克戎相关重症结局的有效性:加拿大免疫研究网络(CIRN)研究

COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study.
PubMed 文献 · Vaccine · 2024-11-30

该回顾性人群队列研究利用加拿大安大略省链接健康行政数据,评估2022年奥密克戎变异株出现后第一年5至11岁儿童COVID-19疫苗对COVID-19相关住院和儿童多系统炎症综合征(MIS-C)的有效性。共纳入1,058,740名儿童,其中583,867名(55.1%)至少接种一剂疫苗。第二剂后7-29天疫苗对住院有效性为93%(95%CI 52-99%),≥120天后降至63%(95%CI 41-77%);至少接种一剂对MIS-C发生率与未接种者无统计学显著差异(aHR=0.71;95%CI 0.38-1.34)。

要点

  • 第二剂后7-29天疫苗对COVID-19相关住院有效性93%(95%CI 52-99%)
  • 第二剂后≥120天疫苗对住院有效性降至63%(95%CI 41-77%)
  • 有基础合并症儿童住院风险显著更高(aHR=4.77;95%CI 3.56-6.38)

核心结论

  • 5至11岁儿童第二剂后前四个月疫苗对COVID-19相关住院有效性高,有合并症儿童重症风险更高,可能从接种中获益最大。

研究设计与样本

  • 回顾性人群队列研究,利用加拿大安大略省链接健康行政数据,纳入1,058,740名5-11岁儿童,研究期为2022年1月2日至12月31日。
  • 采用多变量Cox比例风险回归模型,将接种疫苗作为时变暴露,估计距末次接种不同时间的疫苗有效性,对照为未接种儿童。

主要发现

  • 共纳入1,058,740名儿童,其中583,867名(55.1%)在研究期末至少接种一剂疫苗。
  • 研究期间共发生185例COVID-19相关住院和39例MIS-C。
  • 有基础合并症儿童COVID-19相关住院率显著高于既往健康儿童(aHR=4.77;95%CI 3.56-6.38)。
  • 疫苗对COVID-19相关住院的有效性从第二剂后7-29天的93%(95%CI 52-99%)降至第二剂后≥120天的63%(95%CI 41-77%)。
  • 至少接种一剂疫苗儿童与未接种儿童MIS-C发生率无统计学显著差异(aHR=0.71;95%CI 0.38-1.34)。

关键数值与推荐

  • 第二剂后7-29天疫苗对COVID-19相关住院有效性93%(95%CI 52-99%)。
  • 第二剂后≥120天疫苗对COVID-19相关住院有效性63%(95%CI 41-77%)。
  • 至少接种一剂对MIS-C的aHR=0.71(95%CI 0.38-1.34),无统计学显著差异。

临床怎么用

  • 作者认为有合并症儿童COVID-19相关重症结局风险更高,可能从COVID-19疫苗接种中获益最大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Understanding how the efficacy of COVID-19 vaccines translates from clinical trials to real-world settings is critical to inform evolving vaccination policies. The objective of this study was to assess COVID-19 vaccine effectiveness (VE) against severe COVID-19-related outcomes in children aged 5-11 years, including COVID-19-related hospital admissions and multisystem inflammatory syndrome in children (MIS-C). METHODS: We conducted a retrospective, population-based cohort study using linked health administrative data in the first year following the emergence of the Omicron variant (January 2 to December 31, 2022) in Ontario, Canada. Baseline differences between subgroups of interest were compared using standardized differences. We used multivariable Cox proportional hazard regression models to estimate VE by time since last vaccine dose by treating vaccination as a time-varying exposure, compared to unvaccinated children. RESULTS: We included a total of 1,058,740 children, of which 583,867 (55.1 %) had received at least one vaccine dose by the end of the study period. In total, there were 185 COVID-19-related hospital admissions and 39 cases of MIS-C. The rate of COVID-19-related admission was substantially higher in children with an underlying comorbid condition compared to children who were previously healthy (adjusted hazard ratio [aHR] = 4.77, 95 %CI, 3.56-6.38). VE against COVID-19-related admission ranged from 93 % (95 %CI, 52-99 %) 7-29 days after a second dose to 63 % (95 %CI; 41-77 %) ≥120 days after a second dose. There was no statistically significant difference in the rate of MIS-C in children who received at least one dose of the vaccine compared to unvaccinated children (aHR = 0.71; 95 %CI, 0.38-1.34). CONCLUSIONS: We found that, for children aged 5-11 years, VE against COVID-19-related hospitalization was high in the first four months after a second dose. Children with comorbid conditions were found to be at much higher risk of COVID-19-related severe outcomes and thus may benefit most from COVID-19 vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Piché-Renaud PP, Drover SSM, Austin PC, et al. COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study. Vaccine. 2024. PMID: 39617675. doi:10.1016/j.vaccine.2024.126539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。